- Live market news
- Stocks
- HROW
Harrow Health Inc
HROWStockUSA
Harrow Health Inc
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary.
Latest news on HROWranked by Oyticker for market impact
What HROW filed
- 9 Nov 2026
- 9 Nov 2026
Investor communication
- 5 Oct 2026
Material agreement · Investor communication
OytickerHarrow completes TYRVAYA acquisition, adds FDA-approved nasal spray for dry eye - 4 Sept 2026
- 10 Aug 2026
- 10 Aug 2026
Investor communication
- 6 Aug 2026
Investor communication
- 22 Jun 2026
- 3 Jun 2026
- 11 May 2026
- 11 May 2026
Investor communication
From SEC EDGAR, the public record of what US-listed companies file. Each document opens on sec.gov.
Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.